retatrutide clinical trials results weight loss Lilly orforglipron oral GLP-1 phase 3 trial Retatrutide Weight Loss Treatment Explained
Description
Further, 10 % of weight reduction ameliorated steatosis and lobular inflammation in all patients and ballooning in 90 % of patients [39]
Additionally, the GLP-1receptors have been identified in the GI tracts myenteric and submucosal neural plexuses (18, 19)
GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet
7376 Table 2 summarizes the key studies, their populations, and main findings
